Circulating tumor markers in patients with neuroendocrine tumors-a clinical perspective

Thorvardur R. Halfdanarson; James R. Howe; Sigurdis Haraldsdottir; Thomas M. O'Dorisio

doi:10.2217/IJE.14.38

Circulating tumor markers in patients with neuroendocrine tumors-a clinical perspective

Thorvardur R. Halfdanarson, James R. Howe, Sigurdis Haraldsdottir, Thomas M. O'Dorisio

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Neuroendocrine tumors (NETs) are uncommon malignancies with a very diverse presentation and prognosis. Patients with NETs frequently have circulating tumor biomarkers that may aid in the diagnosis and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to reflect the tumor burden and is useful at the time of diagnosis, and to monitor for recurrence after resection as well as to assess response to systemic therapy. Despite being the best studied marker, chromogranin A has significant limitations. Multiple other biomarkers are in use, but most have not been studied well and need further validation before being recommended for clinical practice. We review both established and novel circulating biomarkers, and highlight some of the limitations of tumor marker use in patients with NETs. 2015

Original language	English (US)
Pages (from-to)	89-99
Number of pages	11
Journal	International Journal of Endocrine Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.2217/IJE.14.38
State	Published - Jan 1 2015

Keywords

5-HIAA
Chromogranin A
Diagnosis
Neuroendocrine tumors
Neurokinin A
Pancreastatin
Prognosis
Serotonin
Tumor markers

ASJC Scopus subject areas

Oncology
Endocrinology, Diabetes and Metabolism
Endocrinology
Cancer Research

Access to Document

10.2217/IJE.14.38

Cite this

@article{1915150d57c24af4806efc0c64c142bf,

title = "Circulating tumor markers in patients with neuroendocrine tumors-a clinical perspective",

abstract = "Neuroendocrine tumors (NETs) are uncommon malignancies with a very diverse presentation and prognosis. Patients with NETs frequently have circulating tumor biomarkers that may aid in the diagnosis and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to reflect the tumor burden and is useful at the time of diagnosis, and to monitor for recurrence after resection as well as to assess response to systemic therapy. Despite being the best studied marker, chromogranin A has significant limitations. Multiple other biomarkers are in use, but most have not been studied well and need further validation before being recommended for clinical practice. We review both established and novel circulating biomarkers, and highlight some of the limitations of tumor marker use in patients with NETs. 2015",

keywords = "5-HIAA, Chromogranin A, Diagnosis, Neuroendocrine tumors, Neurokinin A, Pancreastatin, Prognosis, Serotonin, Tumor markers",

author = "Halfdanarson, {Thorvardur R.} and Howe, {James R.} and Sigurdis Haraldsdottir and O'Dorisio, {Thomas M.}",

year = "2015",

month = jan,

day = "1",

doi = "10.2217/IJE.14.38",

language = "English (US)",

volume = "2",

pages = "89--99",

journal = "International Journal of Endocrine Oncology",

issn = "2045-0869",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Circulating tumor markers in patients with neuroendocrine tumors-a clinical perspective

AU - Halfdanarson, Thorvardur R.

AU - Howe, James R.

AU - Haraldsdottir, Sigurdis

AU - O'Dorisio, Thomas M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Neuroendocrine tumors (NETs) are uncommon malignancies with a very diverse presentation and prognosis. Patients with NETs frequently have circulating tumor biomarkers that may aid in the diagnosis and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to reflect the tumor burden and is useful at the time of diagnosis, and to monitor for recurrence after resection as well as to assess response to systemic therapy. Despite being the best studied marker, chromogranin A has significant limitations. Multiple other biomarkers are in use, but most have not been studied well and need further validation before being recommended for clinical practice. We review both established and novel circulating biomarkers, and highlight some of the limitations of tumor marker use in patients with NETs. 2015

AB - Neuroendocrine tumors (NETs) are uncommon malignancies with a very diverse presentation and prognosis. Patients with NETs frequently have circulating tumor biomarkers that may aid in the diagnosis and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to reflect the tumor burden and is useful at the time of diagnosis, and to monitor for recurrence after resection as well as to assess response to systemic therapy. Despite being the best studied marker, chromogranin A has significant limitations. Multiple other biomarkers are in use, but most have not been studied well and need further validation before being recommended for clinical practice. We review both established and novel circulating biomarkers, and highlight some of the limitations of tumor marker use in patients with NETs. 2015

KW - 5-HIAA

KW - Chromogranin A

KW - Diagnosis

KW - Neuroendocrine tumors

KW - Neurokinin A

KW - Pancreastatin

KW - Prognosis

KW - Serotonin

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=84962263863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962263863&partnerID=8YFLogxK

U2 - 10.2217/IJE.14.38

DO - 10.2217/IJE.14.38

M3 - Review article

AN - SCOPUS:84962263863

SN - 2045-0869

VL - 2

SP - 89

EP - 99

JO - International Journal of Endocrine Oncology

JF - International Journal of Endocrine Oncology

IS - 1

ER -

Circulating tumor markers in patients with neuroendocrine tumors-a clinical perspective

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this